A Phase 3 clinical trial evaluating GZR33 Injection for the treatment of Type 2 Diabetes (T2DM) reached primary completion on 2026-04-07. The study aims to assess the efficacy and safety of GZR33 Injection in patients whose Type 2 Diabetes is inadequately controlled with oral antidiabetic drugs.
Background
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by high blood sugar levels. Liraglutide is an established treatment option for T2DM, often used when oral antidiabetic drugs are insufficient. This trial investigates a new injection, GZR33 Injection, in this patient population.
Trial design
The PHASE3 study, identified as NCT07527078, is evaluating GZR33 Injection against insulin degludec injection (Tresiba®). The trial has an estimated enrollment of 350 participants with Type 2 Diabetes Mellitus who are inadequately controlled with oral antidiabetic drugs. The study's primary objective is to evaluate the efficacy and safety of GZR33 Injection in this patient population.
What this means
The primary completion of this Phase 3 trial signifies that the main data collection for the study's primary endpoints has concluded. This is an important milestone in the development process for GZR33 Injection, moving closer to the potential release of efficacy and safety data for patients with Type 2 Diabetes. Future announcements will provide details on the trial's findings regarding its comparison with insulin degludec injection (Tresiba®).
Source
This update regarding the primary completion of the trial was recorded on ClinicalTrials.gov on 2026-04-07. The full details of the study, NCT07527078, are available on clinicaltrials.gov.